The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...
Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...
Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...
On March 14, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s ...
Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...
EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Zacks Investment Research on MSN3d
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback